| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
53,590,000 |
| Market
Cap: |
365.48(M) |
| Last
Volume: |
10,588,261 |
Avg
Vol: |
1,278,549 |
| 52
Week Range: |
$1.5 - $7.91 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 507 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Emergent BioSolutions is a life sciences company focused on providing a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). Co. is focused on products and solutions that address the following five distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). Co. has a product portfolio of ten marketed products (vaccines, therapeutics, and drug-device combination products).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,919 |
12,919 |
12,919 |
18,361 |
| Total Sell Value |
$75,830 |
$75,830 |
$75,830 |
$128,186 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
3 |
3 |
3 |
6 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-07-15 |
4 |
AS |
$17.75 |
$1,349,353 |
D/D |
(75,433) |
1,113,410 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-07-15 |
4 |
OE |
$7.00 |
$233,331 |
D/D |
33,333 |
1,188,843 |
|
- |
|
| White Marvin L |
Director |
– • – |
2010-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
5,400 |
5,400 |
|
- |
|
| Keese Kyle |
SVP, Mfg Ops |
• – – |
2010-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
5,276 |
14,346 |
|
- |
|
| Biopharm, L.l.c. |
10% Owner |
– – • |
2010-05-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(700,000) |
2,265,043 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
281,190 |
1,155,510 |
|
- |
|
| Sullivan Louis |
Director |
– • – |
2010-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
3,600 |
|
- |
|
| Harsanyi Zsolt |
Director |
– • – |
2010-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
3,600 |
|
- |
|
| Richard Ronald |
Director |
– • – |
2010-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
3,600 |
|
- |
|
| Bailey Sue |
Director |
– • – |
2010-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
3,600 |
|
- |
|
| Hauer Jerome M |
Director |
– • – |
2010-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
3,600 |
|
- |
|
| Hauer Jerome M |
Director |
– • – |
2010-05-17 |
4 |
S |
$16.90 |
$253,500 |
D/D |
(15,000) |
0 |
|
- |
|
| Hauer Jerome M |
Director |
– • – |
2010-05-17 |
4 |
OE |
$3.50 |
$52,500 |
D/D |
15,000 |
15,000 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-05-13 |
4 |
AS |
$17.03 |
$425,750 |
I/I |
(25,000) |
1,524,155 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-05-13 |
4 |
AS |
$17.04 |
$459,945 |
D/D |
(27,000) |
874,320 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-05-13 |
4 |
OE |
$10.13 |
$273,510 |
D/D |
27,000 |
901,320 |
|
- |
|
| Lockhart Stephen |
SVP Product Development |
• – – |
2010-05-10 |
4 |
S |
$15.56 |
$168,048 |
D/D |
(10,800) |
6,980 |
|
- |
|
| Lockhart Stephen |
SVP Product Development |
• – – |
2010-05-10 |
4 |
OE |
$7.00 |
$75,600 |
D/D |
10,800 |
17,780 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-04-29 |
4 |
AS |
$16.53 |
$385,184 |
I/I |
(23,300) |
1,549,155 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-04-28 |
4 |
AS |
$16.50 |
$28,050 |
I/I |
(1,700) |
1,572,455 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-04-21 |
4 |
AS |
$16.00 |
$14,400 |
I/I |
(900) |
1,574,155 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-04-15 |
4 |
AS |
$16.05 |
$67,391 |
I/I |
(4,200) |
1,575,055 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-04-14 |
4 |
AS |
$16.01 |
$214,506 |
I/I |
(13,400) |
1,579,255 |
|
- |
|
| Elsey R Don |
Chief Financial Officer |
• – – |
2010-04-13 |
4 |
OE |
$3.50 |
$17,500 |
D/D |
5,000 |
5,300 |
|
- |
|
| El-Hibri Fuad |
CEO and Chairman |
• • • |
2010-04-12 |
4 |
AS |
$16.08 |
$104,534 |
I/I |
(6,500) |
1,592,655 |
|
- |
|
1294 Records found
|
|
Page 37 of 52 |
|
|
0.16 (2.29%) 
